Literature DB >> 25156883

Morphological parameters able to predict BRAF(V600E) -mutated malignancies on thyroid fine-needle aspiration cytology: Our institutional experience.

Esther Diana Rossi1, Tommaso Bizzarro, Maurizio Martini, Sara Capodimonti, Guido Fadda, Luigi Maria Larocca, Fernando Schmitt.   

Abstract

BACKGROUND: The BRAF(V600E) mutation is the most common diagnostic/prognostic marker in papillary thyroid carcinoma (PTC). Its evaluation is typically performed with DNA-based techniques; nonetheless, a few articles have recently proposed the morphological prediction of BRAF(V600E) in histological PTCs. We investigated this morphological parameter in our cytological series.
METHODS: We re-analyzed all 72 cytohistological samples diagnosed as positive for malignancy (favoring PTC) on fine-needle aspiration cytology from January 2012 to December 2013. We included 22 male patients and 50 female patients. The cytological cases were processed with liquid-based cytology. We performed molecular analysis and immunocytochemistry for the VE1 BRAF(V600E) antibody.
RESULTS: We reported 47 mutated cases and 25 wild-type (WT) cases with 100% cytohistological concordance. The cytological evaluations revealed plump cells (abundant eosinophilic cytoplasm and PTC nuclei) in all 47 mutated cases, with only 6 having a focal plump cell component (≤20% cells). Furthermore, 5 of the 25 WT cases showed focal plump cells. A distinctive sickle nuclear shape was found only in the mutated cases. VE1 yielded 100% positivity for all 24 mutated cases that were tested, including 3 cases with focal plump cells.
CONCLUSIONS: We demonstrated that the BRAF(V600E) mutation might be predicted in cytological samples on the basis of some specific morphological features. Although the detection of plump cells (mainly focal) was also observed in WT cases, the detection of sickle-shaped nuclei provided the highest specificity and sensitivity as a predictive mutational parameter. These morphological features might be a valid tool for selecting cases for molecular analysis.
© 2014 American Cancer Society.

Entities:  

Keywords:  BRAF mutation; liquid-based cytology; plump cells; thyroid carcinoma; thyroid lesions

Mesh:

Substances:

Year:  2014        PMID: 25156883     DOI: 10.1002/cncy.21475

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  9 in total

1.  The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF V600E mutation.

Authors:  Esther Diana Rossi; Tommaso Bizzarro; Sara Granja; Maurizio Martini; Sara Capodimonti; Emilia Luca; Guido Fadda; Celestino Pio Lombardi; Alfredo Pontecorvi; Luigi Maria Larocca; Fatima Baltazar; Fernando Schmitt
Journal:  Endocrine       Date:  2016-08-02       Impact factor: 3.633

2.  Semiquantitative assessment of cytomorphologic features can predict mutation status of thyroid nodules with indeterminate cytologic diagnosis.

Authors:  Maryam Shahi; Stephen J Bloechl; Rachel I Vogel; Rupendra Shrestha; Hannah R Krigman; Maria Evasovich; Lynn A Burmeister; Khalid Amin
Journal:  Hum Pathol       Date:  2019-08-19       Impact factor: 3.466

Review 3.  BRAF Immunohistochemistry Using Clone VE1 is Strongly Concordant with BRAF(V600E) Mutation Test in Papillary Thyroid Carcinoma.

Authors:  Jung-Soo Pyo; Jin Hee Sohn; Guhyun Kang
Journal:  Endocr Pathol       Date:  2015-09       Impact factor: 3.943

4.  BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer.

Authors:  Eleonora Monti; Michela Bovero; Lorenzo Mortara; Giorgia Pera; Simonetta Zupo; Elena Gugiatti; Mariella Dono; Barbara Massa; Gian Luca Ansaldo; Giusti Massimo
Journal:  Int J Endocrinol       Date:  2015-11-26       Impact factor: 3.257

5.  Immunohistochemistry cannot replace DNA analysis for evaluation of BRAF V600E mutations in papillary thyroid carcinoma.

Authors:  Monika Szymonek; Artur Kowalik; Janusz Kopczyński; Danuta Gąsior-Perczak; Iwona Pałyga; Agnieszka Walczyk; Klaudia Gadawska-Juszczyk; Agnieszka Płusa; Ryszard Mężyk; Magdalena Chrapek; Stanisław Góźdź; Aldona Kowalska
Journal:  Oncotarget       Date:  2017-08-24

Review 6.  Somatic mutations in solid tumors: a spectrum at the service of diagnostic armamentarium or an indecipherable puzzle? The morphological eyes looking for BRAF and somatic molecular detections on cyto-histological samples.

Authors:  Esther Diana Rossi; Maurizio Martini; Tommaso Bizzarro; Fernando Schmitt; Adhemar Longatto-Filho; Luigi Maria Larocca
Journal:  Oncotarget       Date:  2017-01-10

7.  New insights into intranuclear inclusions in thyroid carcinoma: Association with autophagy and with BRAFV600E mutation.

Authors:  Suzan Schwertheim; Sarah Theurer; Holger Jastrow; Thomas Herold; Saskia Ting; Daniela Westerwick; Stefanie Bertram; Christoph M Schaefer; Julia Kälsch; Hideo A Baba; Kurt W Schmid
Journal:  PLoS One       Date:  2019-12-16       Impact factor: 3.240

8.  Nuclear Morphological Characteristics in Breast Cancer: Correlation with Hormone Receptor and Human Epidermal Growth Factor Receptor 2.

Authors:  Jiayu Li; Yehan Zhou; Yunzhu Li; Yang Liu
Journal:  Anal Cell Pathol (Amst)       Date:  2021-11-12       Impact factor: 2.916

9.  Molecular Correlates and Nuclear Features of Encapsulated Follicular-Patterned Thyroid Neoplasms.

Authors:  Chan Kwon Jung; Andrey Bychkov; Dong Eun Song; Jang-Hee Kim; Yun Zhu; Zhiyan Liu; Somboon Keelawat; Chiung-Ru Lai; Mitsuyoshi Hirokawa; Kaori Kameyama; Kennichi Kakudo
Journal:  Endocrinol Metab (Seoul)       Date:  2021-02-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.